Ryabtseva Mariya S, Filimonova Marina V, Filimonov Alexander S, Soldatova Olga V, Shitova Anna A, Rybachuk Vitaly A, Volkova Irina K, Nikolaev Kirill A, Kosachenko Alexander O, Koryakin Sergei N, Petrunya Dmitry S, Kotelnikova Polina A, Shemyakov Alexander E, Kolmanovich Danil D, Popov Anton L, Tikhonowski Gleb V, Popov Anton A, Timakova Anna A, Kolobov Andrey V, Deyev Sergey M, Kabashin Andrei V, Zavestovskaya Irina N
P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Leninsky Prospect 53, 119991 Moscow, Russia.
A. Tsyb Medical Radiological Research Center-Branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation, 249036 Obninsk, Russia.
Pharmaceutics. 2025 Apr 15;17(4):515. doi: 10.3390/pharmaceutics17040515.
Proton beam therapy (PBT) is a rapidly advancing modality of hadron therapy. The primary advantage of proton therapy lies in a unique depth-dose distribution characterized by the Bragg peak, which enables a highly targeted irradiation of the area limited to the tumor, while minimizing the impact on healthy tissues. However, a broader clinical adoption of the ion beam therapy is limited by both economic and radiobiological constraints. One of the possible ways to increase the relative biological effectiveness (RBE) of proton therapy involves the use of radiosensitizers. : In this work, we investigated the efficacy of using colloidal solutions of lanthanum hexaboride (LaB) nanoparticles (NPs) coated with polyacrylic acid (PAA) as sensitizers to increase the antitumor biological effectiveness of proton irradiation. This material has not yet been studied extensively so far, despite its promising physical and chemical properties and several reports on its biocompatibility. : LaB NPs were synthesized by femtosecond pulsed laser ablation, functionalized with PAA and characterized. The safety of NPs was evaluated in vitro using a Live/Dead assay on cell cultures: EMT6/P, BT-474, and in vivo in Balb/c mice after intravenous (i.v.) administration. The efficacy of binary proton therapy was evaluated in vitro on cell cultures: EMT6/P, BT-474, and in vivo in the model of human ductal carcinoma of the mammary gland BT-474 in female Nu/j mice after intratumoral (i.t.) administration at a dose of 2.0 mg/mouse and local proton irradiation (fractional exposure of 31 Gy + 15 Gy). The biodistribution of LaB-PAA NPs in the animal body was also evaluated. : Significant enhancement in cancer cell death following proton beam irradiation was demonstrated in vitro on EMT6/P, BT-474 cell lines. Although the antitumor efficacy observed in vivo was comparatively lower-likely due to the high sensitivity of the BT-474 xenografts-both proton monotherapy and binary treatment were well tolerated. : LaB-PAA NPs show promise as efficient sensitizers capable of enhancing the biological efficacy of proton therapy, offering a potential path forward for improving therapeutic outcomes.
质子束治疗(PBT)是一种发展迅速的强子治疗方式。质子治疗的主要优势在于其独特的深度剂量分布,其特征为布拉格峰,这使得能够对局限于肿瘤的区域进行高度靶向照射,同时将对健康组织的影响降至最低。然而,离子束治疗在临床上更广泛的应用受到经济和放射生物学限制。提高质子治疗相对生物效能(RBE)的一种可能方法是使用放射增敏剂。在本研究中,我们研究了用聚丙烯酸(PAA)包覆的六硼化镧(LaB)纳米颗粒(NPs)的胶体溶液作为增敏剂来提高质子照射的抗肿瘤生物效能的效果。尽管这种材料具有良好的物理和化学性质且有几份关于其生物相容性的报告,但到目前为止尚未对其进行广泛研究。通过飞秒脉冲激光烧蚀合成LaB NPs,用PAA进行功能化并进行表征。使用细胞培养物的活/死检测在体外评估NPs的安全性:EMT6/P、BT - 474,以及在Balb/c小鼠静脉内(i.v.)给药后在体内进行评估。在体外对细胞培养物:EMT6/P、BT - 474评估二元质子治疗的效果,以及在雌性Nu/j小鼠的人乳腺导管癌BT - 474模型中,在瘤内(i.t.)以2.0 mg/小鼠的剂量给药并进行局部质子照射(分次照射31 Gy + 15 Gy)后在体内评估。还评估了LaB - PAA NPs在动物体内的生物分布。在体外对EMT6/P、BT - 474细胞系进行质子束照射后,癌细胞死亡有显著增强。尽管在体内观察到的抗肿瘤效果相对较低——可能是由于BT - 474异种移植瘤的高敏感性——但质子单一疗法和二元治疗均耐受性良好。LaB - PAA NPs有望作为能够提高质子治疗生物效能的有效增敏剂,为改善治疗效果提供了一条潜在途径。